Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
AstraZeneca
Moodys
Johnson and Johnson
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,586,238

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,586,238
Title: Enzymatic nucleic acids containing 5\'-and or 3\'-cap structures
Abstract:An enzymatic nucleic acid molecule comprising a 5\'- and/or a 3\'-cap structure, wherein said structure is not a 5\'-5\'-linked inverted nucleotide or a 3\'-3\'-linked inverted nucleotide.
Inventor(s): Matulic-Adamic; Jasenka (Boulder, CO), Beigelman; Leonid (Longmont, CO), Karpeisky; Alexander (Boulder, CO), Jarvis; Thale (Boulder, CO), Usman; Nassim (Boulder, CO), DiRenzo; Anthony (Boulder, CO), Wincott; Francine (Longmont, CO)
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:09/419,125
Patent Claims:1. A nucleic acid molecule comprising a 5'-cap structure, a 3'-cap structure, or both a 5'- and a 3'-cap structure, wherein said 5'-cap structure is selected from the group consisting of 4',5'-methylene nucleotide; 1-(.beta.-D-erythrofuranosyl) nucleotide; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 12-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,5-dihydroxypentyl nucleotide; and 5'-mercapto moieties, and wherein said 3'-cap structure is selected from the group consisting of 1,5-anhydrohexitol nucleotide; L-nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,5-dihydroxypentyl nucleotide; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; and 1,4-butanediol.

2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in an enzymatic nucleic acid molecule.

3. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in an antisense nucleic acid molecule.

4. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis delta virus, group I intron, VS RNA or RNase P RNA motif.

5. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said 5'-cap structure.

6. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said 3'-cap structure.

7. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said 5'-cap structure and said 3'-cap structure.

8. The nucleic acid molecule of claim 1, wherein said 5'- and 3'-cap structures are different.

9. The nucleic acid molecule of claim 1, wherein said 5'- and 3'-cap structures are same.

10. The nucleic acid of claim 1, wherein said 3'-cap structure is a 3'-2' linked inverted nucleotide.

11. The nucleic acid of claim 1, wherein said 3'-cap structure is a 3'-2' linked inverted abasic moiety.

12. The nucleic acid of claim 1, wherein said 5'-cap structure is a 1,3-diamino-2propyl phosphate group.

13. The nucleic acid of claim 1, wherein said 5'-cap structure is a L-nucleotide.

14. The nucleic acid of claim 1, wherein said 5'-cap structure is a threo-pentafuranosyl group.

15. The nucleic acid of claim 1, wherein said 5'-cap structure is a 3,5-dihydroxypentyl nucleotide.

16. The nucleic acid of claim 1, wherein said 5'-cap structure is a 1-(.beta.-D-erythrofuranosyl) nucleotide.

17. The nucleic acid of claim 1, wherein said 3'-cap structure is a L-nucleotide.

18. The nucleic acid of claim 1, wherein said 3'-cap structure is a 3,5-dihydroxypentyl nucleotide.

19. An isolated mammalian cell comprising the nucleic acid molecule of claim 1.

20. The mammalian cell of claim 19, wherein said mammalian cell is a human cell.

Details for Patent 6,586,238

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2016-04-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2016-04-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2016-04-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 6,586,238

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Johnson and Johnson
Merck
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.